JNJ-42165279

JNJ‑42165279 is an investigational small molecule drug developed by Janssen Pharmaceutica (Janssen-Cilag) that acts as a potent and selective inhibitor of the enzyme fatty acid amide hydrolase (FAAH), with an IC₅₀ of 70 nM for human FAAH. It covalently binds to FAAH but is slowly reversible and highly selective, showing minimal activity against other enzymes, ion channels, transporters, or receptors. By inhibiting FAAH, it increases levels of endocannabinoids such as anandamide (AEA), oleoyl ethanolamide (OEA), and palmitoyl ethanolamide (PEA). The drug has been investigated primarily for the treatment of anxiety disorders—including social anxiety disorder—and major depressive disorder with anxious distress. Clinical development has reached Phase II trials in these indications[1][3][5][6][8].

Other names

N-(4-Chloropyridin-3-yl)-4-((2,2-difluorobenzo[d][1,3]dioxol-5-yl)methyl)piperazine-1-carboxamide1346528-50-4AH2E5UQ11YAH-2E5UQ11YAH 2E5UQ11Y